THE STATE OF CHINA BIOTECH

Facts and Figures from ChinaBio
Part I - Driving Factors and Government Programs
Recorded on: January 13, 2009
Runtime: 00:10:43

There has been much debate on the state of new drug development in China. Are there novel molecules being discovered there? What is the level of clinical trial activity? Are VCs investing in China? What about M&A and IPOs?

Greg Scott, President of ChinaBio, presents research data for 2008 for the first time, at an executive workshop held at Wilson Sonsini Goodrich & Rosati in San Francisco during the JP Morgan 27th Annual Healthcare Conference.

In this segment, Mr. Scott highlights 10 driving factors behind China's biopharmaceutical industry, and specifically the major government programs as one of the key factors.

Tags: China, ChinaBio, Greg Scott, China biotech, MOST, Ministry of Science and Technology, MOH, Ministry of Health, Zhangjiang Hi-Tech Park, Zhongguancun Life Science Park, BioBay, TEDA, Chine Academy of Sciences, CAS, China Academy of Medical Sciences, CAMS, 863 Program, Mega New Drug Development Program